Journal article
7760 Identifying Conventional and Novel Biomarkers to Predict Checkpoint Inhibitor Associated Autoimmune Diabetes
L Wu, J Wentworth, C Liddle, M Carlino, D Brown, RJ Clifton-Bligh, G Long, S Sasson, V Tsang, A Menzies, JE Gunton
Journal of the Endocrine Society | The Endocrine Society | Published : 2024
Abstract
Abstract Disclosure: L. Wu: None. J. Wentworth: None. C. Liddle: None. M. Carlino: Consulting Fee; Self; Amgen Inc, Bristol-Myers Squibb, Novartis Pharmaceuticals, Pierre Fabre, Regeneron Pharmaceuticals, Roche Pharmaceuticals, Merck, Sanofi. D. Brown: None. R.J. Clifton-Bligh: None. G. Long: Consulting Fee; Self; Amgen Inc, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Merck, Novartis Pharmaceuticals, Pierre Fabre, Regeneron Pharmaceuticals, Sandoz. S. Sasson: None. V. Tsang: None. A. Menzies: Consulting Fee; Self; Bristol-Myers Squibb, Novartis Pharmaceuticals, Roche Pharmaceuticals, Pierre Fabre. J.E. Gunton: None. Introduction: Checkpoint inhibito..
View full abstract